The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded glucagon-like ...

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped ...

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (NYSE:HIMS), an estimated $18.07 million trade based on quarterly average pricing.

Investing.com -- Hims & Hers Health Inc was upgraded to “Neutral” from “Underperform” by Bank of America, which said a new agreement with Novo Nordisk removes a key legal risk that had weighed on the ...

Novo Nordisk drops patent lawsuit against Hims & Hers after agreement to sell branded weight loss medicines on Hims platform. Shares of Hims & Hers jump 36%.

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.

Hims & Hers Health (NYSE:HIMS) shares climbed about 10% on Tuesday, extending Monday’s sharp rally of nearly 49% after analysts upgraded the stock following the company’s newly announced partnership ...